Companies House · 02158996

ZENTIVA PHARMA UK LIMITED

UK registered company, private limited company, incorporated 28 Aug 1987.

Active
50
Public contracts
0
Spend payments
Total spend

ZENTIVA PHARMA UK LIMITED is a UK company registered at Companies House under number 02158996. This page links its registry record to its activity in UK public procurement — the contracts it has been awarded and the transparency-spend payments recorded against it.

Companies House record

Company number
02158996
Status
Active
Company type
Private Limited Company
Incorporated
28 Aug 1987
Country of origin
United Kingdom
Registered office
12 NEW FETTER LANE, LONDON, EC4A 1JP, ENGLAND
Nature of business (SIC)
46460 - Wholesale of pharmaceutical goods
Accounts category
FULL
View source on data.gov.uk

Public sector contracts

Contract awards linked to ZENTIVA PHARMA UK LIMITED.

ProcurementBuyerAwardedValue
Medicinal Products Dynamic Purchasing System (131864)Procurement & Logistics Service
Proprietary DrugseTenderwales
Generic Drugs - Topicals & MiscellaneousVelindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on behalf of All Wales Health Boards and Trusts)
Proprietary DrugsVelindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on behalf of All Wales LHB's and Trusts)
Generic Drugs - Tablets & CapsulesVelindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on behalf of All Wales LHB's and Trusts)
Generic Drugs - Tablets & CapsulesVelindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on behalf of All Wales LHB's and Trusts)
Generic Injections/Infusions 4Velindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (On Behalf of all Wales) Health Boards
Generic Drugs - Topicals & MiscellaneousVelindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on behalf of All Wales LHB's and Trusts)
NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025NHS England
Medicinal Products and Pharma Funded Homecare Services (5315742) - Pre - Market EngagementRegional Business Services Organisation Procurement and Logistics Service
Medicinal Products and Pharma Funded Homecare Services (5315742) - Pre - Market EngagementRegional Business Services Organisation Procurement and Logistics Service
Biologic and Biosimilar MedicineseTenderwales
NHS National Framework for the supply of Pomalidomide commencing 1 April 2025NHS England
NHS National Framework for the supply of Pomalidomide commencing 1 April 2025NHS England
NHS National Framework for the supply of Pomalidomide commencing 1 April 2025NHS England
NHS National Framework for Transition products commencing 1 October 2024NHS England
NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024NHS England
Generic Drugs - Tablets & CapsulesVelindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services ( on behalf of All LHB's and Trusts )
NHS National Framework for Transition Products (Nintedanib and Dalbavancin)NHS England
Medicinal Products Dynamic Purchasing System (131864)Regional Business Services Organisation, Procurement and Logistics Service
Medicinal Products Dynamic Purchasing System (131864)Regional Business Services Organisation, Procurement and Logistics Service
Medicinal Products Dynamic Purchasing System (131864)Procurement & Logistics Service
NHS National Transition Framework for Apremilast, Pazopanib and DapagliflozinNHS England
NHS National Framework for Transition Products (Nintedanib and Dalbavancin)NHS England25 Feb 2026£14.8m
NHS National Transition Framework for Apremilast, Pazopanib and DapagliflozinNHS England25 Nov 2025£25.9m
NHS National Framework for Denosumab Injection commencing 1st January 2026NHS England North East & Yorkshire29 Sept 2025£37.7m
NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025NHS England30 Jun 2025£986.3m
NHS National Framework for Transition products (Nilotinib and Ticagrelor)NHS England North East & Yorkshire11 Jun 2025£22.1m
NHS National Framework for Transition products (Nilotinib and Ticagrelor)NHS England North East & Yorkshire11 Jun 2025£22.1m
NHS Framework Agreement for Branded Medicines - Proprietary Category TenderNHS England24 Mar 2025£1.2bn
CM/TNS/24/5719 - NHS National Framework for the supply of PomalidomideNHS England20 Feb 2025£17.1m
CM/TNS/24/5713 - NHS Framework for Transition products - 1 February 2025NHS England14 Jan 2025£9.9m
NHS National Framework for Transition products commencing 1 October 2024NHS England29 Sept 2024£16.2m
NHS Branded Medicines Tranche Framework for London and South of EnglandNHS England21 Jul 2024£381m
NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024NHS England4 Apr 2024£1bn
NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 1)NHS England4 Mar 2024£1
NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024NHS England26 Jan 2024£688m
NHS South of England Branded Medicines - Tranche A - September 2023NHS England17 Jul 2023£249.8m
NHS London Branded Medicines - Tranche B - September 2023NHS England13 Jul 2023£231.1m
NHS National Generic Pharmaceuticals Wave 14bATAMIS LTD6 Jul 2023£428.2m
NHS National Generics Pharmaceuticals Transition 2023_1NHS england4 May 2023£57.6m
NHS Framework Agreement-Branded Medicines - National Proprietary PharmaceuticalsNHS England23 Apr 2023£304.5m
NHS National Generics Pharmaceuticals - Dasatinib and Paliperidone InjectionNHS england27 Mar 2023£27m
NHS Midland & East Branded Medicines, Tranche B & Annual TrancheNHS England13 Feb 2023£480.4m
NHS Framework for North of England Branded Medicines Tranche A & Annual TrancheNHS England8 Feb 2023£262m
NHS National Generic Pharmaceuticals Wave 14aNHS England14 Dec 2022£208m
NHS National Pharmaceuticals Transition 2022_1NHS England and NHS Improvement18 Jul 2022£39.6m
NHS National Pharmaceuticals Transition 2022_1NHS England and NHS Improvement18 Jul 2022£39.6m
NHS Framework Agreement for South of England Branded - Tranche B and AnnualNHS England14 Jul 2022£338.7m
NHS Framework Agreement for London, Branded Medicines - Tranche A and AnnualNHS England14 Jul 2022£153.8m

Supplier identities

How this company appears as a supplier across the data.

FAQs about ZENTIVA PHARMA UK LIMITED

Is ZENTIVA PHARMA UK LIMITED an active company?

ZENTIVA PHARMA UK LIMITED (company number 02158996) is recorded as "Active", incorporated on 28 Aug 1987.

What does ZENTIVA PHARMA UK LIMITED do?

Its Companies House nature-of-business (SIC) is: 46460 - Wholesale of pharmaceutical goods.

Has ZENTIVA PHARMA UK LIMITED won UK public-sector contracts?

Yes — 50 public-sector contract awards are linked to this company in our data.

Where is ZENTIVA PHARMA UK LIMITED based?

Its registered office is 12 NEW FETTER LANE, LONDON, EC4A 1JP, ENGLAND.

Understand any company's public-sector footprint

Enable links Companies House to live procurement and spend data — see contracts, buyers and payments for any UK supplier.

Get in touch with Enable